Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a…
<!-- Name:DistributionId Value:8846954 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4577 -->…
Browsing Tag
AntiCTLA4
Anti-CTLA-4 Monoclonal Antibodies Market Set to Register a Steady Revenue CAGR of 8.3% by 2031 |…
<!-- Name:DistributionId Value:8832227 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:True -->
<!-- Name:IcbCode Value:2790 -->…
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody ADG126 By Investing.com
Adagene (ADAG) Presents Clinical Data for Anti-CTLA-4 SAFEbody ADG126
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced interim results from its…
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in…
SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a clinical trial collaboration with…
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor…
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in 2022 to report results of ADG126 dose escalation in…
Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold…
SAN DIEGO and SUZHOU, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel…
Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody…
SAN DIEGO and SUZHOU, China, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel…
Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal…
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based…